Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04253652
Other study ID # FGC19002
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date March 9, 2023
Est. completion date December 2024

Study information

Verified date October 2022
Source The Functional Gut Clinic
Contact Anthony Hobson
Phone 01613027777
Email anthony@thefunctionalgutclinic.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Many patients that are prescribed iron report gastrointestinal side effects. This research project aims to investigate if the gastrointestinal symptoms of taking iron supplementation are related to changes in gases produced by bacteria in the gastrointestinal tract.


Description:

This study is a pre-post interventional, two armed prospective cohort study where patients who are newly diagnosed with iron deficiency anaemia are prescribed iron therapy (either oral iron supplements, 200mg capsules containing 65mg of iron 2-3 times daily, or intravenous iron 1000-1500mg) as part of their standard care. Participants will be asked to provide breath samples and complete the IBS-SSS questionnaire at baseline and after 4 weeks of taking the iron therapy as part of their standard care. A diary including stool consistency and frequency will also be completed by participants on a daily basis. For further exploratory research, some participants from each the oral and IV iron arm will be asked to provide stool samples at baseline and 4-weeks post iron therapy to assess any microbiome changes in response to iron therapy.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 155
Est. completion date December 2024
Est. primary completion date September 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Written informed consent before participating in the study after being given a full description of the study and prior to any study-specific procedures being performed. 2. Male or non-pregnant female and is age 18 years to 80 years. 3. Can communicate well with the Investigator and to comply with the requirements for the entire study. 4. Capacity to understand written English. 5. New diagnosis iron-deficient anaemia. 6. Prescribed IV iron therapy or oral iron supplementation which contains 65mg elemental iron, two or three times per day for a period of at least 1 month or, will receive 1000mg or 1500mg of intravenous iron, as part of their standard care. 7. Participant agrees to wait until after taking baseline breath samples and completing the IBS-SSS questionnaire before starting their iron therapy. 8. Participant agrees to follow pre-test diet for 24 hours before giving test sample. 9. Participant agrees to refrain from strenuous physical activity on the day of the breath test. 10. Refrain from smoking on the day of the breath test. 11. Agree to complete an overnight fast on the night before the breath test. Food and drink must be withheld until after all breath test samples have been taken. 12. No probiotics for 14 days before the breath test or during the study. 13. Body mass index between 18.5 and 34.9kg/m2 (bounds included). 14. Not antibiotics for 4-weeks before the start of the study or during the study Exclusion Criteria: 1. Using an opioid based medication. 2. Antibiotics in the 4 weeks prior to enrolment. 3. Colonoscopy/sigmoidoscopy in the 1 week prior to enrolment, unless they have taken their baseline breath sample and IBS-SSS questionnaire before completing the required bowel preparation. 4. Diagnosis of any organic gastrointestinal disease, including inflammatory bowel disease, coeliac disease and diverticulitis. 5. Mechanical obstruction of the GI tract. 6. Participant is diabetic. 7. Participant has any hepatic disease. 8. Participant has any disease of the CNS. 9. Participant is involved in this study as an Investigator, sub-Investigator, study coordinator, other study staff, or sponsor member. 10. Previous abdominal or colorectal surgery except appendectomy, cholecystectomy, or hysterectomy. 11. Participant has had iron therapy in the 12 months prior to enrollment.

Study Design


Intervention

Other:
Fasted breath samples
Will be completed pre and post iron therapy
IBS-SSS
Will be completed pre and post iron therapy
Daily diary
Monitoring stool form, consistency and frequency on a daily basis for 4 weeks
Exploratory research: stool samples
Completed pre and post iron therapy for a subset of patients enrolled in the study

Locations

Country Name City State
United Kingdom Sheffield Teaching Hospitals Sheffield

Sponsors (3)

Lead Sponsor Collaborator
The Functional Gut Clinic Anglia Ruskin University, Sheffield Teaching Hospitals NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Exploratory Qualitative and Quantitative data for faecal microorganisms at baseline and 4-weeks since commencing iron therapy. 4 weeks apart
Primary Breath Difference in methane levels in breath samples from baseline and 4-weeks since commencing iron therapy. This will be measured in parts per million (ppm). 4 weeks apart
Secondary Irritable Bowel Syndrome Symptom Severity Score (IBS-SSS) Comparison in change of IBS-SSS score from baseline to 4 weeks since commencing iron therapy. The minimum score is 0 and maximum score is 500. The greater the score, the worse the severity and frequency of symptoms of abdominal pain and distention, and increased dissatisfaction of overall bowel functioning. 4 weeks apart
Secondary Stool consistency Change in stool frequency and form according to the bristol stool chart and abdominal symptoms during the 4 weeks since commencing iron therapy. 4 weeks apart
See also
  Status Clinical Trial Phase
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Recruiting NCT06292949 - Clinical Study of Resistant Starch in Improving Constipation N/A
Recruiting NCT04132661 - MRI Assessment of Mode of Action of Bisacodyl, Single Dose Phase 4
Terminated NCT02839889 - Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation) Phase 4
Completed NCT02726295 - The Efficacy of Mutaflor(E. Coli Nissle 1917, Mutaflor®) for Chronic Constipation:Multicenter Study Phase 4
Recruiting NCT02255747 - Anal Dilatation for Infants and Children With Constipation N/A
Completed NCT02246647 - Biomarkers for Intestinal Permeability in Patients With Constipation
Completed NCT01566409 - Maintenance Treatment for Children With Constipation N/A
Completed NCT02863848 - Effect of Inulin-type Fructans on Constipated Children. N/A
Completed NCT01695915 - Diurnal Variation in Rectal Diameter N/A
Completed NCT02658201 - Ultrafast MRI Imaging to Exclude Constipation N/A
Completed NCT01710579 - Normal Values in Ano-rectal 3D High Resolution Manometry N/A
Completed NCT01474499 - A Trial of Docusate Sodium and Sorbitol Rectal Solution for the in Patients With Constipation Phase 3
Completed NCT01411501 - Efficacy and Safety of Acupuncture for Functional Constipation Phase 3
Completed NCT01438567 - A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy Phase 3
Completed NCT01170039 - The Effectiveness of Lubiprostone in Constipated Diabetics Phase 4
Completed NCT00931853 - Efficacy and Tolerability of Cassia Fistula Plus Senna Alexandrina Miller (Sugar Free) in the Chronic Functional Constipation (CFC). Phase 3
Active, not recruiting NCT02442115 - Impact of Improving GI Symptoms on Autism Symptoms and Oxidative Stress
Completed NCT00994851 - Evaluation of Cassia Fistula + Senna Alexandrina Miller in the Chronic Functional Constipation Treatment. Phase 3
Terminated NCT01003249 - Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen Phase 4